Molecular beacons (MBs) are dual-labeled oligonucleotides that fluoresce only in the presence of complementary mrna. the use of MBs to target specific mrnas allows sorting of specific cells from a mixed cell population. In contrast to existing approaches that are limited by available surface markers or selectable metabolic characteristics, the MB-based method enables the isolation of a wide variety of cells. For example, the ability to purify specific cell types derived from pluripotent stem cells (pscs) is important for basic research and therapeutics. In addition to providing a general protocol for MB design, validation and nucleofection into cells, we describe how to isolate a specific cell population from differentiating pscs. By using this protocol, we have successfully isolated cardiomyocytes differentiated from mouse or human pscs (hpscs) with ~97% purity, as confirmed by electrophysiology and immunocytochemistry. after designing MBs, their ordering and validation requires 2 weeks, and the isolation process requires 3 h.
IntroDuctIon
The ability to separate different cell types is important for a wide range of biological and medical studies, including the quantification of cells with specific phenotypes for disease diagnosis, the isolation of terminally differentiated induced PSCs (iPSCs) at different stages of maturation and the selection of cells from a mixed cell population that possess unique characteristics or functions. In most cases, the selection and separation methods rely on cell physical properties (e.g., size, shape, stiffness), cell surface protein expression or genetic modifications. Cells derived from PSCs, including embryonic stem cells (ESCs) and iPSCs 1, 2 , are becoming powerful tools that markedly change how pharmaceuticals are developed and validated for therapies by allowing patient-specific mechanistic studies and personalized drug testing for efficacy and toxicology. For example, researchers have used cells derived from PSCs to model genetic diseases such as long QT syndrome 1 (refs. 3,4) . However, PSC-based disease modeling is challenging, as many disorders affect only specific, terminally differentiated cell populations. Currently available PSC differentiation systems typically generate mixed populations containing undifferentiated cells or undesirable cells, which could cause teratoma formation or interfere with high-throughput quantification 5 . Thus, purification of tightly controlled populations of terminally differentiated cells derived from PSCs is desirable to prevent detrimental effects, and it is an example of a potential application for cell sorting technologies.
Methods developed to isolate specific populations of differentiated cells derived from PSCs
Various techniques have been developed to isolate specific cell types from differentiating PSCs, including positive selection 6, 7 , negative selection 8 , genetic modification 9,10 and metabolic negative selection 11, 12 . The most popular method for isolating specific populations of cells is to use antibodies to target surface proteins 6, 7 . However, the lack of specific cell surface proteins that can be targeted by conventional antibody-based fluorescence-activated cell sorting (FACS) remains one of the major challenges commonly encountered when isolating terminally differentiated cells from differentiating PSCs. Several methods that do not require specific antibodies are available, including the classic purification technique that relies on a fluorescent reporter gene driven by a promoter such as NK2 homeobox 5 (NKX2-5), ISL LIM homeobox 1 (ISL1) or myosin heavy chain beta (MYH7) in genetically modified cell lines 6, 7 . However, such reporter gene-based methods may not be applicable to certain PSCs, such as iPSCs in which selecting a line with the reporter gene (such as GFP) integrated at a single, correct genomic location is very challenging. Alternatively, nongenetic approaches such as the use of a Percoll gradient 13 or the use of cell metabolism 12, 14 have been developed. Although these methods are useful in specific applications, they are limited to targeting specific cellular phenotypes, which may be dynamic during the differentiation process 6 . Together, these methods may lack the required detection specificity owing to the absence of a molecular marker that is highly expressed in target cell types. To address the limitations of the above approaches, we developed a method to isolate specific cell types by directly targeting intracellular mRNAs using MBs and sorting via FACS.
Development of the protocol
MBs are dual-labeled oligonucleotides ~15-30 bases long with a fluorophore on one end and a quencher molecule on the other end ( Fig. 1a; ref. 15) . Since their development in 1996 (ref. 15) , MBs have been used to identify specific mRNA or DNA sequences in solution 16, 17 and to visualize the intracellular localization of mRNA transcripts in individual living cells 18, 19 . MBs are excellent in both types of applications because they fluoresce only when hybridized to complementary oligonucleotides; this property confers molecular specificity and target versatility. In the absence of an oligonucleotide target, MBs assume a hairpin conformation that brings the fluorophore and quencher moieties into contact, resulting in marked quenching of the fluorophore and very low background fluorescence (Fig. 1a) . Hybridization of the MB with target oligonucleotide sequence opens the hairpin, separating the
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fluorophore from the quencher and restoring fluorescence upon excitation ( Fig. 1) .
It was demonstrated in proof-of-concept studies that MBs could be used in a flow cytometry assay to identify cells expressing a specific mRNA in a mixed cell population without affecting the expression of this mRNA 20 . We have recently developed an MBbased method for the isolation of cardiomyocytes (CMs) from a differentiating culture of PSCs by targeting highly expressed specific mRNAs 21, 22 . Specifically, we designed and validated MBs targeting cardiac troponin T (cTNT or TNNI3) or myosin heavy chain beta (MYH7) mRNAs, respectively, which are highly expressed in CMs. MBs were then delivered into differentiating mouse or hPSCs using nucleofection followed by FACS sorting of CMs on the basis of MB signal. Control studies confirmed that CM-specific MBs had low background signal in all non-CM cells in the differentiating culture of PSCs, confirming detection specificity. We found that 97% of mouse or human cells isolated using FACS on the basis of MB signal demonstrated CM-like characteristics in assays including electrophysiology, flow cytometry and immunocytochemistry. This approach, using a FACS sorter to purify CMs on the basis of MB signal from specific mRNA expression, is very versatile and can be adopted for the isolation of other cell types from differentiating PSCs. Although the later steps of the PROCEDURE (Step 18 onward) use the isolation of CMs from differentiating hPSCs as an example application, this part of the protocol can be readily modified to isolate other specific cell types provided that MBs have been successfully designed to target genes highly expressed in the cell type of interest.
Experimental design
There are five essential elements of the MB-based protocol for the isolation of a specific cell type from differentiating cells ( Fig. 2) : (i) identification of specific mRNAs that are highly expressed only in the desired cell type in a mixed cell population (Fig. 2a) ; (ii) design and validation of MBs targeting specific mRNAs with high signal-to-background ratio, S/N (Fig. 2b) ; (iii) delivery of MBs into a mixed population of cells, e.g., from differentiating PSCs with high efficiency (Fig. 2c) ; (iv) isolation of cells with FACS based on MB signal (Fig. 2d) ; and (v) validation of cell characteristics (Fig. 2e) . Although the experimental design described here uses the isolation of CMs as an example, the MB-based method can be readily modified for the isolation and enrichment of other cell types by designing MBs to target the specific gene(s) highly expressed in the particular cell type, as described below.
Identification of specific mRNAs highly expressed in target cells. To use MBs to isolate specific cells from a mixed cell population, target mRNAs that are highly expressed only in the cell type of interest must be identified. These mRNAs need to have a relatively high abundance so that when MBs are hybridized to their mRNA targets in the specific cells (such as CMs), the resulting fluorescence signal is at least fivefold higher than that in other cell types. Genes encoding structural proteins have been used by several groups in the past 21, 23 . However, for isolating novel cell types, the gene expression profile must be quantified using reverse-transcription PCR (RT-PCR or DNA microarray) to identify specific mRNAs that have high levels of expression Hybridization induces a conformational change that separates the fluorophore from the quencher, resulting in a more than tenfold increase in fluorescence signal. (c) A schematic of a positive control MB with a fluorescent dye attached to both the 5′ and 3′ ends, and thus it is always fluorescent upon excitation. This probe is used to determine whether MBs can be delivered into different cell types efficiently and uniformly. (d) A schematic depicting a specific negative control beacon. The four mutated bases should prohibit hybridization of the probe to the target region of specific mRNA. When delivered into HL-1 as positive control cells, this control beacon should yield very low background signal, confirming the MB's specificity. (e) A predicted secondary structure of a cardiac-specific gene, with a single-stranded region highlighted and expanded. Figure (panels a,b) reproduced from ref. 24 . (more than tenfold) compared with those in other cell types in the PSC differentiation culture (Fig. 2a) . It may be necessary to choose multiple target genes that are highly expressed in the cell type of interest so that at least one mRNA will be specific enough and result in high MB signal. This also raises the possibility of using multiple MBs to target a specific subpopulation, such as ventricular CMs rather than all CMs. MBs can be designed to target human genes, mouse genes, or in some cases both. An MB can be designed for both human and mouse genes only when the selected target sequence is identical for mouse and human genes. Specifically, MBs targeting the MYH7 or TNNT2 mRNA described in this protocol were designed for both mouse and human genes, allowing the use of HL-1 CMs (a mouse cell line) for characterization of CM-specific MBs. If an MB is designed for applications with human cells, but the MB targeting sequence does not have a perfect match in the mouse gene, a separate positive control cell line consisting of a standard control cell (e.g., 293 or 3T3 cells) transfected with a plasmid to highly express the target human gene should be used for MB validation. If an MB is designed only for isolating CMs from mouse cells, using HL-1 CMs as a positive control is sufficient.
Design and validation of MBs targeting specific mRNAs.
Once specific genes are identified, MBs can be designed by targeting regions of the corresponding mRNA where excellent probe accessibility and signal specificity can be achieved. The target sequences of a specific mRNA may not be accessible owing to the secondary structure of the mRNA or RNA-binding proteins. To enhance target accessibility, an RNA secondary structure prediction program (e.g., mFOLD) can be used to identify potential single-stranded regions of the mRNA (Fig. 1d) . It is also important to select target sequences with a sufficient (35-65%) GC content so that MBs so designed will have a good affinity to their targets. Finally, a National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) search is typically performed to identify unique sequences of the mRNA for MBs to target (target sequences) and to minimize the number of sequences that differ from a target sequence by only a few (<5) bases. Steps 1-10 identify and use three oligonucleotide sequences: the target sequence, an MB with its loop and stem sequences, and a mismatched (mutant) sequence. The target sequence in the specific mRNA needs to be carefully selected to ensure MB signal specificity. The MB loop sequence is complementary to the target sequence, and the MB stem sequence is typically five nucleotides long with high GC content. The MB is formed by selecting a dyequencher pair and conjugating the dye and quencher to the 5′ and 3′ ends of the MB sequence, respectively. The most affordable options are the FAM fluorophore with Black Hole Quencher 1 or the Cy3 fluorophore with Black Hole Quencher 2. The use of Cy3 dye is recommended for experiments where another molecule is taking up the FITC/GFP wavelengths or there is significant autofluorescence. For labs without an oligonucleotide synthesizer facility, it is recommended to order MBs from one of the many high-quality oligonucleotide providers such as Integrated DNA Technologies (IDT) and Eurofins MWG Operon, where HPLC purification of the MBs to eliminate the free dye is performed. A mismatched sequence, which typically contains 4-6 mutations compared with the target sequence, is used to test the quality of MB synthesis in vitro. As it is impossible to accurately predict target accessibility in living cells, multiple (three to five) MBs are usually designed and tested against a specific mRNA.
The most important issue with the MB-based approach is signal specificity. Ideally, MBs delivered into a mixed cell population show a high level of signal only in target cells but not in other cell types owing to the high expression of the gene in target cells. However, in certain cases, a high level of nonspecific signal from MBs may occur because of the delivery method (such as microinjection), MB degradation or MB-protein interactions in cells. To determine MB signal specificity, a negative control random MB was designed whose loop sequence was generated using 'random walk' and does not match with any mRNA sequence in the genome of interest. Any signal from the random MBs after delivery into the target cells or positive control cells (cells highly express the target gene, such as the Hl-1 cells for CM isolation) will be nonspecific background signal. The ratio of MB signal from specific mRNA to the background signal from random MB gives the signal-to-noise ratio (S/N). To have high signal specificity, the MB designed should have a S/N >5 in target cells.
In addition to using a random MB as a negative control, two assays can be performed to further confirm signal specificity. The first uses a mutant MB that has a 4-5 base mismatch with the target sequence (Fig. 1c) . After delivery into the positive control cells (e.g., HL-1 cells), such a mutant MB should only generate a low background signal. The second assay downregulates the expression level of the target mRNA using RNA interference (siRNA) in the positive control cells or upregulates the expression level using a plasmid in a cell type unrelated to the target cells, such as mouse embryonic fibroblasts (MEFs) for CM isolation. High MB specificity is ensured if the MB signal decreases after downregulation and increases after upregulation of the target gene. Plasmid expression in a control cell type (such as MEFs) is a reliable method, but it is less ideal compared with the siRNA approach, as the MB accessibility might be different from that encountered when the gene is expressed endogenously. Note that the same MB design may have different target accessibilities in human and mouse cells.
Delivery of MBs into a mixed population of cells with high efficiency and throughput.
Uniform, rapid delivery of MBs into all cell types in the differentiating culture of PSCs is important. For MBs to increase their fluorescence intensity by 5-10-fold upon hybridizing to their complementary mRNA targets, cells need to take up a sufficient number (usually >2,000) of MBs per transfection. This is based on the estimate that the ideal number of mRNA transcripts per cell is ≥200 for effective isolation using FACS. The large MB/mRNA ratio ensures that most (if not all) mRNA targets in a cell are hybridized by MBs.
There are several MB delivery methods, including the use of microinjection, cell-penetrating peptides (CPPs), streptolysin O (SLO) and electroporation 24 . Microinjection is of low throughput, and it often interferes with normal cell function. Although the CPP-or SLO-based delivery of MBs could have high efficiency and throughput, the delivery efficiency is typically cell typedependent and may not work for the mixed cell population resulting from PSC differentiation. In addition, CPP-or SLO-based delivery of MBs might lead to endosomal entrapment and degradation, causing a high level of background signal. Electroporation has been used to deliver oligonucleotides into living cells, but conventional methods may result in low cell viability. Recent advances in electroporation technology (such as nucleofection) have led to a reduction in the harmful events, including heat generation, metal ion dissolution, pH variation and oxide formation. The advanced electroporation methods lead to cellular internalization of oligonucleotide probes with high transfection efficiency ( >90%) and high cell viability >80%; ref. 22) . By using nucleofection, it is possible to uniformly deliver MBs into millions of cells within 20 min. Because MBs must be delivered into cells quickly because of the inherently short functional lifespan of exogenous nucleic acid sequences in a cellular environment 25 , we recommend delivery via nucleofection. It is also important to isolate cells on the basis of the MB signal within 4 h to avoid potential artifact caused by MB degradation. MBs may be reintroduced into cells at later time points if necessary, and several groups have shown that the MB signal from each delivery becomes undetectable after 24 h (ref. 26) . Small numbers of MBs may enter the cell nucleus; however, the resulting fluorescence signal should be low, as no target mRNA is present in the nucleus, and the probability of random genomic integration of MBs is negligible 19, 20, 24, 27, 28 .
It is also important to ensure that the difference in MB signal between target cells and other cell types is not an artifact due to the preferential uptake of MBs by a specific cell type. It is therefore necessary to determine whether or not all cells in the mixed population take up MBs uniformly (Fig. 2c) . To this end, the random sequence MB is modified to have two identical fluorophores instead of a dye-quencher pair ( Fig. 1c ) and used as a delivery control probe for delivery studies. After probe delivery into differentiating cells, fluorescence signals are quantified and a relatively uniform signal distribution is expected. This experiment is designed to confirm that the MB signal specificity is due to MB hybridization to target mRNAs rather than to MBs preferentially entering one cell type but not others.
Isolation of target cells with FACS based on MB signal.
FACS sorting is currently the only method that can selectively isolate a specific cell population at a rate of millions of cells per hour on the basis of fluorescence. As MBs can detect cells that express various levels of target mRNAs, the flow cytometry assay may not generate very distinct populations of cells if there is a large variation of target mRNA expression levels in the differentiating PSCs to which MBs are delivered. It is therefore crucial to design MBs that target abundantly expressed mRNAs in cells of interest in order to isolate them with high specificity and throughput. It is also important to fine-tune the FACS parameters so that cells with low levels of fluorescence signal will not be isolated. In addition, the FACS output streams should be carefully analyzed for the effect of sorting on both the cell viability and cell yield. Cell viability can be assessed by plating the MB-positive population and measuring cell death over a 2-d period after sorting. To assess the yield of the FACS-based target cell isolation, cell populations with high MB signal (MB positive) and low MB signal (MB negative) are collected after the sorting experiment, and both populations are compared using RT-PCR and functional assays. A significant difference in target cell characteristics (such as specific gene expression) between the MB-negative and MB-positive populations may be used as an indication to confirm that MB-based sorting has a high specificity.
Target cell characterization using qRT-PCR and immunocytochemistry. To ensure that a high-purity target cell population is isolated from differentiating PSCs, MB-positive cells must be tested to ascertain that (i) they highly express the specific gene(s) and (ii) they have low (or zero) expression levels of genes associated with other cell lineages. For example, to isolate CMs, specific markers such as TNNT2, TNNI3, MYH7 and MYL2 can be analyzed in the MB-positive population using both RT-PCR and immunocytochemistry to obtain population-based results and quantitative information on the number of cells expressing specific markers. It is also necessary to demonstrate that the MB-positive cells do not express genes that are markers of other cell types, including skeletal muscle, neural progenitor cells, fibroblasts and endothelial cells. To ensure that the MB-positive cells represent a high-purity population of target cells, a high percentage of cells expressing specific markers and a low percentage of cells expressing markers indicating other cell lineages are required.
Applications
The MB-based method presents a novel approach for cell isolation owing to its versatility and its ability to target intracellular mRNAs. A major hurdle to the current use of cells differentiated from hPSCs for many applications is the potential tumorigenicity or aberrant tissue formation after cell transplantation. As many types of cells do not have specific surface protein markers for isolation and it is still impractical to genetically modify human iPSCs to express a selection marker, the MB-based method may offer a useful means of purifying specific cells such as CMs generated from PSCs. The MB-based method is applicable to the isolation of any cell type that expresses specific gene marker(s) to which corresponding MBs can be designed and validated. No surface protein marker for isolation is required. For example, MBs can be designed to target specific genes that are highly expressed only within neuronal or pancreatic beta cells, so the MB-based method can be used to isolate neurons or beta cells generated from PSCs with high purity. MBs could also be used as a tool to evaluate cell differentiation protocols to provide rapid feedback on the yield and efficiency of the process.
In addition to isolating specific cells from the mixed cell population of differentiating PSCs, the MB-based approach can also be applied to the isolation and enrichment of pure cell populations after transdifferentiation, in which one mature somatic cell type is transformed into another mature somatic cell type without undergoing a pluripotent state or using a progenitor cell type as an intermediate step. Another potential application of the MB-based method described in this protocol is to isolate gene-modified cells after precise genome editing using transcription activator-like effector nucleases (TALENs) and clustered regularly interspersed short palindromic repeat (CRISPR)/Cas systems. The modification of an endogenous gene is often in the form of single-base mutation (or correction of single-base mutation), deletion or insertion, making the selection of gene-modified cells very challenging. With the addition of few wobble mutations in the target gene, MBs could be designed to target the site of modification in the corresponding mRNA, and the gene-modified cells could be isolated using the method described here.
• •
proceDure cell-specific MB design • tIMInG 10 d 1| Identification of genes to target. Identify genes that are highly expressed in target cells on the basis of a literature search, experience and/or prior results. For example, for isolating CMs, we chose cTNT and MYH7 as target genes. Check whether the genes identified are also highly expressed in other cell types in the mixed cell population during PSC differentiation; high mRNA expression in other cell types could lead to an inability to separate target cells from mixed cell population.
2|
Confirmation of high gene expression levels using RT-PCR. Prepare total RNA from at least 100,000 cells from the specific cell population using the RNeasy mini plus kit according to the manufacturer's instructions.
3|
Convert the RNA into cDNA using the iScript cDNA synthesis kit from Bio-Rad or an equivalent system.
4|
Perform either Taqman or SYBR Green real-time PCR for each sample in multiplexed reactions performed in triplicate using a 7500 Fast real-time PCR system or equivalent. Run all annealing steps at 60 °C.
5|
Normalize all target genes to GAPDH. Calculate differences in cycle threshold (C t ) values (∆C t = C t gene of interest-C t GAPDH in experimental samples) for each target mRNA by subtracting the mean value of GAPDH (relative expression = 2 − ∆CT ). Proceed with the mRNA for which the highest ratios between the target gene and GAPDH are obtained.
6|
Prediction of the secondary structure of the target mRNA. Enter the sequence into a secondary structure prediction program (e.g., mFOLD) to predict single-stranded regions in the target mRNA.
7|
Designing the MB loop region. Identify a sequence of 15-30 bases of the target mRNA predicted to be single-stranded. Select a region with 35-65% GC content, and design a complementary sequence with a predicted melting temperature (T m ) of 60 °C in 150 mM NaCl when it hybridizes to the target mRNA (the prediction of T m could be performed using the online tool 'HyTher', available at http://ozone3.chem.wayne.edu/). This sequence (the reverse-complement of the mRNA target sequence) will form the loop of the MB and ensure that the MBs will be able to hybridize to the target sequence. If the positive control cells are from a different species than that of the target cells, MBs should be designed to target mRNA sequences that are identical in both species (such as mouse and human). If the target sequence in the gene of interest is not identical for both species, positive control cells should be generated to highly express the target gene by transfecting a cell line unrelated to the target cells with a plasmid encoding the target gene. ? trouBlesHootInG 8| Add a stem to the loop sequence by appending complementary arms of five bases long to the 3′ and 5′ ends of the loop sequence, respectively. MBs with a total length of more than 40 bases may form a secondary structure, and therefore it should be avoided. It may be desirable to add only one arm with a five-base sequence complementary to the loop sequence on the opposing end in order to create a shorter MB (shared-stem MB). A five-base stem with a GC content of ~60% should be strong enough to generate a stem-loop hairpin structure with a T m of ~50 °C, which can be determined using the online tool 'DNA Mfold' (available at http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form).  crItIcal step Do not use guanine for the first three bases at the 5′ end because of its tendency to quench fluorophores. ? trouBlesHootInG 9| Use NCBI BLAST to identify other mRNAs to which the MB may hybridize in the cell type of interest. To do this, use the MB sequence as input. The closest match should be the target mRNA sequence identified in Step 7, and the second closest match should have a mismatch of at least 4 bp compared with the mRNA target sequence.
10|
Design a mismatched target sequence. By using the results of the NCBI BLAST search from Step 9, the second closest sequence could be used as the 'mismatched sequence' if it contains 4-6 bases that are not complementary to the beacon loop sequence. If the second closest sequence from the BLAST search has more than six bases that are not complementary to the beacon loop sequence, design a new 'mismatched sequence' by mutating four randomly selected bases in the target sequence.
11| MB formation.
To form the MB, select a dye-quencher pair (as discussed in the Experimental design section) and conjugate the dye and quencher to the 5′ and 3′ ends of the MB sequence, respectively. To reduce background signal, attach the quencher to the 3′ end to ensure that all MBs will have a quencher even if the fluorophore is not conjugated to the MB because of a synthesis error. To determine MB performance, the synthetic target oligonucleotide (usually single-stranded DNA) with the same sequence as target mRNA and mutant (mismatched) oligonucleotide should also be obtained for MB characterization in solution. Usually MBs with DNA backbones are sufficient for cell isolation. It may be necessary to design and test several (3-5) target cell-specific MBs, which can be ordered simultaneously to reduce wait times. ? trouBlesHootInG 12| Resuspend all oligonucleotides in nuclease-free, 0.1× TE (pH 7.0) buffer at 100 uM to make stock solutions.  crItIcal step Avoid freeze-thaw cycles to preserve the stability and function of MBs.  pause poInt MBs can be stored at −20 or −80 °C for up to 6 months after synthesis.
MB validation in solution • tIMInG 2 h 13|
Use the MB buffer mimicking cytosolic conditions (139 mM K, 12 mM Na, 4 mM Cl ), and make a 500-µl aliquot of 1 µM cell-specific MBs. Use the same buffer in separate tubes to dilute the target oligonucleotide and mismatched oligonucleotide to a 1.5 µM concentration. Make serial dilutions of the target and mismatched oligonucleotides, respectively, to establish dose dependence. ? trouBlesHootInG 14| Add 25 µl of MB solution to each well of a 384-well black-bottomed plate, and then add 25 µl of each concentration of the solutions containing the target oligonucleotide or mismatched oligonucleotide to their designated wells. Include one blank well and one well with DNase 1 as negative and positive controls, respectively. Incubate at 37 °C for 5 min to allow the solutions to equilibrate.
15| Analysis of the fluorescence intensity of MBs using a microplate reader.
Use a microplate reader to determine the fluorescence intensity of each well. From this, establish a dose-dependence curve using the serial dilutions of the target oligonucleotide. The MB signal at the highest target oligonucleotide concentration should generally be 5-30 times higher than the background signal quantified in the negative control experiment in which the signal level of MBs without any target is measured. The MB signal in the well with the highest concentration of mismatched oligonucleotide should be no more than 1.5 times the background signal. Candidate MBs that do not meet these conditions should be disregarded owing to lack of specificity and low S/N. Select MBs that satisfy these conditions for further testing. 
16|
Plate the cells for the delivery test (e.g., MEFs) at 50-60% confluency in DMEM medium containing 10% (vol/vol) FBS, and then culture them overnight at 37 °C.
17|
Add the delivery control MB (see Reagents) to the nucleofection solution to obtain an MB concentration of 500 nM.  crItIcal step To check the efficiency of MB delivery via nucleofection and to select optimal delivery conditions, a delivery control MB (Fig. 1c) is designed, which has a nonspecific 'random' sequence with two FAM dyes conjugated to both 5′ and 3′ ends, allowing the probe to fluoresce without any target when delivered into living cells using nucleofection.
18| Detach and suspend one million cells (from Step 16) per condition and wash them with PBS.
19| Centrifuge the cells at 90g for 10 min at room temperature. The centrifugation should be gentle to avoid damaging the cells. Remove the supernatant, allowing the cell pellet to remain undisturbed.  crItIcal step Ensure that all of the PBS is removed from the solution to avoid diluting the electroporation solution.
20|
Resuspend the cell pellet in the nucleofection solution that contains delivery control MBs (from Step 17).
21|
After MB delivery, gently centrifuge the cells at 90g for 10 min at room temperature, and then aspirate the medium. Resuspend the cells in PBS and analyze the cells using any standard flow cytometer to determine MB delivery efficiency. For flow cytometry assays, first run an untransfected sample. Use this nonfluorescent sample to set the lower limits of gates that can be used to detect MB-positive cells. ? trouBlesHootInG 22| Optimization of nucleofection parameters. Perform nucleofection using a variety of programs to identify the optimal program with the highest uniform delivery efficiency. Changes in the electroporation program do affect cell viability, so great care must be taken to choose a program that does not kill a large number of cells. Immediately after nucleofection, gently pipette the cells from the cuvette into cell culture medium and keep them there for at least 10 min.
MB specificity testing in positive and negative control cells, respectively • tIMInG 1 d 23| Delivery of cell-specific MBs into positive control cells using nucleofection.
Use the optimized nucleofection parameters and the procedure described in Steps 16-21 to deliver the cell-specific MBs designed in Steps 1-11 and tested in Steps 13-15 into positive control cells (e.g., HL-1 cells for CM isolation).
24| Delivery of negative control MBs to positive control cells. Repeat
Step 23 to deliver the negative control MB (see Reagents) into a separate aliquot of positive control cells. As a further negative control, deliver the mutant negative control MB (Fig. 1d) into a separate aliquot of positive control cells, as described in Step 23.
25| Delivery of cell-specific MBs into other cell types using nucleofection.
Deliver the cell-specific MBs into any other cell types you are using as controls (e.g., smooth muscle cells, aortic endothelial cells and cardiac fibroblasts typically present in the differentiating PSCs). Use the optimized nucleofection parameters and the procedure described in Steps 16-22.
26|
Analyze all cells after MB delivery using flow cytometry. After MB delivery, incubate the cells for 10 min at 37 °C, gently centrifuge the cells at 90g for 10 min at room temperature and then aspirate the medium. Resuspend the cells in PBS and analyze the cells using any standard flow cytometer. Use negative control cells to set the gates as in Step 21 .  crItIcal This step should result in a strong fluorescent signal from cell-specific MBs in positive control cells (Step 23), low (typically ≤3%) fluorescence signal from the negative control (mutant) MBs (Step 24; Fig. 3 ) and low false-positive signal resulting from nonspecific opening of the random MBs in other cell types (Step 25; Fig. 3b) .  crItIcal step The flow cytometry analysis must be performed within 2 h of MB delivery into the cells. Several groups have shown that nonspecific MB signal may increase quickly ~2 h after MB delivery owing to MB degradation, resulting in a high level of false positives in flow cytometry analysis 18, 25 . ? trouBlesHootInG 27| Selection of the final cell-specific MBs. Repeat Steps 23-26 to select the final MB designs, which result in high fluorescence signal in positive control cells (such as HL-1) and very low background fluorescence signal in negative control cells (such as non-CM cells). These MBs will be used for further study for the isolation of target cells. In most of the cases, one cell-specific MB that has satisfactory performance (high positive signal and low background signal) will be sufficient. stem cell differentiation • tIMInG ~2-3 weeks  crItIcal Any differentiation protocol may be used for the selection/enrichment of the cell type of interest. The following steps represent the method used for the isolation of CMs as an example. Alternatively, prepare CMs differentiated from hPSCs using any of the previously validated protocols 5, [29] [30] [31] .
28|
Culture undifferentiated hPSCs on either mitotically inactivated MEF (STO) cells in DMEM/F12 supplemented with 20% (vol/vol) serum replacement, 1% (vol/vol) l-glutamine, 1% (vol/vol) non-essential amino acids, 100 mM β-mercaptoethanol and 4 ng/ml basic fibroblast growth factor, or culture cells in feeder-free systems 32 . Change the medium every day, and transfer hPSCs to new feeder cells every 5-7 d. Culture the cells for at least one passage after thawing before beginning differentiation. 30| Dissociation of hPSCs from feeder cell culture. When colonies are 80% confluent, remove hPSC culture medium and rinse it with DMEM/F-12 medium. Add 3 ml of dispase (1 mg/ml) to the hPSC culture, and incubate it for ~20 min at 37 °C to dissociate the cells into small clusters (10-20 cells). There may be some batch-to-batch variation for dissociation time, and thus frequent microscopic examination ensures successful dissociation, especially after 15 min, from the addition with dispase. Once dissociation is completed, add 7 ml of DMEM/F12 medium to the cell suspension and transfer it to a conical tube. Centrifuge the cell suspension at room temperature at 300g for 5 min to collect the cells. Repeat this procedure twice to make sure that the dispase is completely removed.
31|
Start of 2D hPSC differentiation. Resuspend the cells in 5 ml mTeSR 1 medium, and transfer the cells onto Matrigel-coated plates from Step 29. Culture the cells for 24-48 h in 10 ml mTeSR medium to allow them to expand.
32| Induction of mesodermal differentiation.
Replace the medium with cytokine medium and incubate the cells for 2 d.
33|
Remove the cytokine medium and add END-2-conditioned medium, and then incubate the cells for 4 d.
34|
Supplementation with isoproterenol to produce mature CMs. If desired, remove the conditioned medium and incubate the cells with mTeSR medium containing isoproterenol (10 µM), a β-adrenergic receptor agonist, for at least 4 d to generate spontaneously beating CMs.
Deliver MBs into differentiating hpscs for the isolation of target cells • tIMInG 6 h 35| Gentle dissociation of intact differentiated cells using Accutase. Rinse one million cells from
Step 34 with PBS, and then incubate them for 20 min with 2 ml of Accutase at 37 °C.
36| Add 6 ml of DMEM/F12 containing 10% (vol/vol) FBS to neutralize the Accutase before centrifuging cells at 90g for 10 min at room temperature and aspirating the supernatant.
37|
Resuspend the cells in nucleofection solution containing 500 nM delivery control MBs.
38|
Use the optimal nucleofection program identified to deliver MBs into the mixed cell population. Immediately after nucleofection, gently pipette the cells from the cuvette into the DMEM/F12 medium containing 10% (vol/vol) FBS, and incubate the cells for 30 min at 37 °C. Resuspend the cells in PBS, and sort the MB-positive cells using a cell sorter such as the FACS Aria II or a Jazz system. Use slightly more stringent gating conditions than those in the previous analysis ( Step 41) to ensure high purity of isolated target cells. Gating strategies can be altered to provide the desired purity level by using more stringent conditions. Plate the cells on appropriate dishes (multielectrode array plates, six-well dishes and so on) in DMEM/F12 medium containing 10% (vol/vol) FBS, and incubate the cells for 24-48 h for subsequent target cell characterization assays.
39|
? trouBlesHootInG Troubleshooting advice can be found in table 1. Step 43, characterize the target cells purified with cell-specific MBs: 2-7 d
antIcIpateD results
We have used the protocol described herein to enrich and isolate homogeneous populations of target cells from PSC differentiation culture with high throughout and high ( >95%) purity 21 . Well-designed MBs targeting mRNAs specific for the cell type of interest should show high S/N (Fig. 4a) , whereas an MB targeting a poorly selected sequence could result in high nonspecific signal (Fig. 4a) . It is also necessary to perform cellular tests of multiple MBs with positive control cells, even for well-designed MBs, to ensure that at least one MB gives high fluorescence signal level, as not all MBs are able to access the target mRNA sequence (Fig. 4b) . For example, in our published studies 21 , we delivered four MBs into positive control cells (HL-1 CM) and found that two MBs (named MHC-1 MB and MHC-2 MB, respectively) designed to target the MYH7 mRNA displayed high fluorescence signal, whereas two MBs (named TNT1 MB and TNT2 MB, respectively) targeting the TNNT2 mRNA showed relatively low signal (table 2). We therefore selected the MHC-1 MB that gave the highest signal level for subsequent CM isolation studies. Optimally designed MBs will give high fluorescence signal in positive control cells (Fig. 4b) and very low signal in all other cell types-e.g., smooth muscle cells and cardiac fibroblast cells chosen to represent cells that may be present in differentiating PSCs for CM isolation (Fig. 4c) . It may also be necessary to use negative control MBs to confirm the signal specificity in positive control cells, as shown in showed a high level of MB signal, and FACS sorting isolated 49.2% cells as mouse CMs. As PSC-derived cells may express high, medium or low levels of the target gene, the FACS results may be less clear-cut than that in the positive control cells, as reflected by the lack of distinct populations in the FACS results shown in Figure 4d . However, the percentage of FACSisolated cells based on MB signal should correlate well with differentiation efficiency-i.e., the expected proportion of target cells in the differentiating culture. This can be used to fine-tune the FACS protocol and to obtain an initial confirmation of appropriate MB function. After isolating MB-positive cells from the mixed cell population using FACS, it is necessary to confirm the characteristics of the target cells using RT-PCR, immunocytochemistry, action potential measurements or other functional assays. It is expected that the expression of cell-specific genes (e.g., TNNT2 and MYH7 for CMs) increases in MB-positive cells compared with that of the mixed cell population (Fig. 4e) . The expression of gene markers from alternative lineages (e.g., Acta2 and Sox17) should show the reverse trend (Fig. 4e) . Further, it is anticipated that the vast majority ( > 98%) of the MB-sorted cells are positive for the specific protein marker, as is the case for MB-sorted CMs that highly expressed the cardiac marker Actn2, as revealed by immunocytochemistry (Fig. 4f) . 
